NCT06881017View on ClinicalTrials.gov

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

August 1, 2029

Study Completion Date

November 1, 2029

Conditions

Gastric CancerHER2 + Gastric CancerCLDN18.2-positive Adenocarcinoma of the Gastroesophageal JunctionPD-L1 Positive

Interventions

DRUG

Trastuzumab

iv，d1

DRUG

Adebrelimab

iv，d1，q3w

DRUG

Apatinib

po，qd，d1-21，q3w

DRUG

S-1

po，bid，d1-14，q3w

DRUG

Capecitabine

po，bid，d1-14

DRUG

Oxaliplatin

iv，d1，q3w

DRUG

zolbetuximab

iv，d1

DRUG

SHR-A1811

iv，d1 ，q3w

DRUG

SHR-A1904

iv，d1 ，q3w

DRUG

SHR-1701

iv，d1 ，q3w

All Listed Sponsors

lead

China Medical University, China

OTHER